Join us to expand your horizons
in the Japanese pharma market
Meet Dr.Reddy’s API team at
CPHI Japan, 2023
Booth 5J-2019-21 April 2023
Tokyo Big Sight, Tokyo,Japan
Nirav Shah
Vice President and
Region Head
Takayuki Hato
Regional Sales Lead,
Sales and Marketing
Masahiro Wakabayashi
Regional Sales Manager,
Sales and Marketing
Rohan kaushik
Associate VP, Business Development,
Sales and Marketing
Aditya Gudimella
Associate Director, Marketing
Our Team at
CPHI Japan
About CPHI Japan
CPHI Japan is the premier event for the pharmaceutical industry in Japan, providing a platform for international companies to connect and do business with key players in the Japanese market. In its 20th anniversary, the event is expected to attract over 200 exhibitors from across the entire pharmaceutical supply chain, showcasing the latest products, solutions, and innovations in the industry.
Attendees can expect to discover the latest products and services from ingredients, contract services, and biopharma to technology, packaging, and machinery. They will also have the opportunity to meet and network with industry leaders, search for potential partners, and arrange meetings with potential partners online through the event's chat service.
Whether you are a large multinational corporation or a small start-up, CPHI Japan provides the perfect platform to expand your horizons in the Japanese pharmaceutical market. Join us at the event and take advantage of the unique opportunities to connect and grow your business.
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Our Achievement
2021
21/01/2021
Best Supply Chain Team
of the Year - Pharma- 2021
2021
11/11/2021
The winner of the Corporate
social responsibility (CSR)
Initiative of the year at Global
generics & Biosimilars Awards
2021
07/10/2021
The winner of the Best Indian
Company in the US -
Manufacturing
Sector for the year 2021
COVID-19: Prime Minister
of India Meets Pharma leaders
On October 23, 2021, Prime Minister Narendra
Modi met Indian COVID-19 vaccine manufacturers,
including Dr. Reddy's. During the meeting,
2021
21/01/2021
Best Supply Chain Team
of the Year - Pharma- 2021
2021
11/11/2021
The winner of the Corporate
social responsibility (CSR)
Initiative of the year at Global
generics & Biosimilars Awards
2021
07/10/2021
The winner of the Best Indian
Company in the US -
Manufacturing
Sector for the year 2021
COVID-19: Prime Minister
of India Meets Pharma leaders
On October 23, 2021, Prime Minister Narendra
Modi met Indian COVID-19 vaccine manufacturers,
including Dr. Reddy's. During the meeting,
Manufacturing Location
Renuncia
Ninguna información en este catálogo, incluida cualquier referencia a cualquier producto o servicio, constituye una oferta de venta, ni debe interpretarse como representación de una oferta de venta. Los productos protegidos por patentes válidas no se ofrecen ni se suministran para uso comercial. Sin embargo, las cantidades de investigación de dichos productos pueden ofrecerse con el fin de presentaciones reglamentarias, siempre que existan dichas exenciones reglamentarias. Los compradores deben realizar una evaluación independiente del escenario de la patente para sus respectivos mercados y serán responsables de todas las responsabilidades relacionadas con la patente. Los productos protegidos por patentes válidas en la India no están disponibles para uso comercial, pero estarían disponibles para los fines de la Sección 107A.